BIOMARK APPOINTS DR. JEAN-FRANCOIS HAINCE AS STRATEGIC ADVISOR TO GUIDE ITS EXPANSION INTO QUEBEC
![biomark appoints dr jean francois haince as strategic advisor to guide its expansion into quebec](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-appoints-dr-jean-francois-haince-as-strategic-advisor-to-guide-its-expansion-into-quebec.jpg)
Vancouver, British Columbia – (September 16th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Jean-Francois (Jeff) Haince as a strategic advisor to its management team. Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Haince into our advisory team. […]
BIOMARK TEAM INVITED FOR FULL APPLICATION FOR SPARKS GRANT COMPETITION
![biomark team invited for full application for sparks grant competition](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-team-invited-for-full-application-for-sparks-grant-competition.jpg)
Vancouver, British Columbia – (September 14th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that 2 of its most recent abstract submissions for the Novel Technology Application in Cancer Prevention and Early Detection Spark Grants competition have resulted in invitations to submit full applications for funding. This […]
BIOMARK TEAM SECURES HEALTH CANADA LETTER OF NO OBJECTION FOR ITS GLIOBLASTOMA CLINICAL TRIAL
![biomark team secures health canada letter of no objection for its blioblastoma clinical trial](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-team-secures-health-canada-letter-of-no-objection-for-its-blioblastoma-clinical-trial.jpg)
Vancouver, British Columbia – (August 27th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that Health Canada has approved its clinical trial application (CTA) and has granted a Letter of No Objection (NOL) for its application entitled ACETYL-AMANTADINE AS A BIOMARKER IN PATIENTS WITH GLIOBLASTOMA. The company […]
BioMark Diagnostics Expands Research Development in Quebec
![biomark expands research and development in quebec](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-exapands-research-and-development-in-quebec.jpg)
Vancouver, British Columbia – (August 13th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate diagnostic solutions announced today that the Company is moving parts of its lung cancer research and development operations to LE CAMP, an incubator-accelerator dedicated to tech businesses growth and mentorship. […]
BioMark’s Affiliated Company, Bio-Stream Diagnostics Inc. Announces Partnership with Qatar University ML Team for Development of COVID-19 Testing
![biostream announces partnership with Qatar University for covid 19 testing](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biostream-announces-partnership-with-Qatar-University-for-covid-19-testing.jpg)
The Company will leverage Raman spectroscopy and Machine Learning as part of its diagnostics Vancouver, British Columbia – (July 21, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that its affiliated company, Bio-Stream Diagnostics Inc., will be working with University of Qatar’s Dr. Somaya Al-Maadeed in the development of […]
BioMark Diagnostics Inc. Receives Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name “BioMark”
![biomark receives full registered trademark from USPTO](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-receives-full-registered-trademark-from-USPTO.jpg)
Vancouver, British Columbia – (July 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that the Company has been granted a Full Registered Trademark Status from the US Patent and Trademark Office for its Company Brand Name “BioMark”. The term “BioMark” was selected by the company in reference to […]
BioMark Diagnostics Announces Peer Reviewed Publication on Detection of Cancer
![biomark announces peer reviewed publication on detection of cancer](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-announces-peer-reviewed-publication-on-detection-of-cancer.jpg)
Vancouver, British Columbia – (June 23 , 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate cancer diagnostic solutions to assist in detecting, monitoring and assessing treatment for cancer early and cost effectively, announced today a peer reviewed scientific publication to support its innovative cancer […]
BioMark Receives European Patent for Cancer Diagnostic
![biomark receives european patent for cancer diagnostic](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-receives-european-patent-for-cancer-diagnostic.jpg)
Vancouver, British Columbia – (June 18, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) announced today that the company has been granted a patent titled “A METHOD FOR ASSAYING THE ACTIVITY OF SPERMIDINE/SPERMINE N1-ACETYLTRANSFERASE.” The method comprises correlating a presence of the acetylated metabolite of rimantadine or tocainide to spermidine/spermine N1-acetyltransferase […]
BIO STREAM DIAGNOSTICS INC. SELECTED FOR CDL RAPID RESPONSE INNOVATION PROGRAM
![biostream selected for cdl rapid response program](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biostream-selected-for-cdl-rapid-response-program.jpg)
Vancouver, British Columbia – (June 16, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that its affiliated company, Bio Stream Diagnostics Inc., was selected to participate in the global academic science and tech startup program Creative Destruction Lab’s (CDL) recent dedicated Recovery program. CDL Recovery is designed […]
BioMark Diagnostics Inc. Clarifies Prior Disclosure
![biomark clarifies prior disclosure](https://www.biomarkdiagnostics.com/wp-content/uploads/2021/05/biomark-clarifies-prior-disclosure.jpg)
Vancouver, British Columbia – (June 11 , 2020) – – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a developer of proprietary, non-invasive, and accurate diagnostic solutions which can help detect, monitor and assess cancer early and cost effectively, wishes to include additional information to clarify the disclosures in its news release disseminated […]